ALXN Alexion Pharmaceuticals Inc.

104.81
+3.47  (+3%)
Previous Close 101.34
Open 101.6
Price To Book 2.31
Market Cap 23,501,219,083
Shares 224,226,878
Volume 1,767,409
Short Ratio
Av. Daily Volume 2,392,065
Stock charts supplied by TradingView

NewsSee all news

  1. Alexion Announces Appointment of Tanisha Carino, Ph.D., as Chief Corporate Affairs Officer

    - Dr. Carino to head up newly integrated Corporate Affairs function including global government affairs, public policy and communications - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of

  2. Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases

    - Elamipretide in Phase 3 development for primary mitochondrial myopathy - - If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive

  3. Alexion to Report Third Quarter 2019 Results On Wednesday, October 23, 2019

    Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2019 before the US financial markets open on October 23, 2019. Following

  4. Alexion Announces CFO Succession

    - Aradhana Sarin, M.D., to become CFO after filing of Q3 2019 results - - Paul Clancy to step down as CFO and serve as senior advisor through mid-2020 - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced

  5. Alexion and BridgeBio Announce Japanese License Agreement for Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine

    - Eidos grants Alexion exclusive license to develop and commercialize AG10 in Japan - - Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. & Europe; Phase 3 trial in ATTR polyneuropathy planned to

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b/3 trial to be initiated in 2020 with data due in 2021.
CAEL‐101
AL amyloidosis
FDA Approval announced June 27, 2019.
Eculizumab
Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
PDUFA data under priority review October 19, 2019.
ALXN1210
atypical Hemolytic Uremic Syndrome (aHUS)
FDA approval announced December 21, 2018.
ULTOMIRIS (ravulizumab-cwvz)
Paroxysmal nocturnal hemoglobinuria (PNH)
Approval announced October 23, 2017.
Eculizumab
Refractory generalized myasthenia gravis (gMG)
Phase 3 enrolment to be completed early 2020.
ALXN1840 (WTX101)
Wilson disease
Phase 3 trial initiated 1Q 2019.
ULTOMIRIS (ravulizumab-cwvz)
Generalized myasthenia gravis (gMG)
Phase 1b/2a data due 2H 2019. Phase 2/3 trial to be initiated early 2020.
ALXN1830
Warm autoimmune hemolytic anemia (WAIHA)
Phase 3 PK data due early 2020.
ULTOMIRIS (ravulizumab-cwvz) subcutaneous
Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS)
Phase 3 trial to commence 1H 2020.
ULTOMIRIS
Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)
Phase 3 trial to commence by the end of 2019.
Eculizumab
Generalized myasthenia gravis (gMG) - children
Phase 3 trial to commence by the end of 2019.
Eculizumab
Neuromyelitis Optica Spectrum Disorder (NMOSD) - children

Latest News

  1. Alexion Announces Appointment of Tanisha Carino, Ph.D., as Chief Corporate Affairs Officer

    - Dr. Carino to head up newly integrated Corporate Affairs function including global government affairs, public policy and communications - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the appointment of

  2. Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases

    - Elamipretide in Phase 3 development for primary mitochondrial myopathy - - If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive

  3. Alexion to Report Third Quarter 2019 Results On Wednesday, October 23, 2019

    Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2019 before the US financial markets open on October 23, 2019. Following

  4. Alexion Announces CFO Succession

    - Aradhana Sarin, M.D., to become CFO after filing of Q3 2019 results - - Paul Clancy to step down as CFO and serve as senior advisor through mid-2020 - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced

  5. Alexion and BridgeBio Announce Japanese License Agreement for Eidos' Transthyretin Amyloidosis (ATTR) Investigational Medicine

    - Eidos grants Alexion exclusive license to develop and commercialize AG10 in Japan - - Phase 3 study of AG10 in ATTR cardiomyopathy underway in U.S. & Europe; Phase 3 trial in ATTR polyneuropathy planned to

  6. Alexion to Present at the 17th Annual Morgan Stanley Global Healthcare Conference

    Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 17th Annual Morgan Stanley Global Healthcare Conference in New York, NY on Monday, September 9th, 2019 at 8:45 a.m. ET. An

  7. Alexion Announces Upcoming Data Presentations at 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

    - Five abstracts accepted, including new long-term data from PREVENT trial of SOLIRIS® (eculizumab) in adults with anti-AQP4 antibody-positive NMOSD - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that

  8. Alexion to Present at the 14th Annual Citi Biotech Conference

    Alexion Pharmaceuticals (NASDAQ:ALXN) today announced that management will present at the 14th Annual Citi Biotech Conference in Boston, MA on Wednesday, September 4th, 2019 at 12:00 p.m., ET. An audio webcast of the

  9. European Commission Approves SOLIRIS® (eculizumab) For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)

     - SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Europe - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63%

  10. European Commission Approves SOLIRIS® (eculizumab) For the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder (NMOSD)

     - SOLIRIS® (eculizumab) is the first and only approved medication for NMOSD in Europe - - 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63%